Bristol-Myers Squibb

How Bristol Myers Squibb's Celgene Buyout Continued to Pay Off in Q4
Motley Fool
Thu, 02/4/21 - 08:07 pm
Bristol-Myers Squibb
Celgene
earnings
M&A
Bristol Myers makes late play for COVID-19 antibody space, picking up 2 early-phase molecules from Rockefeller
Fierce Biotech
Wed, 02/3/21 - 10:56 am
Bristol-Myers Squibb
antibodies
COVID-19
Bristol Myers Squibb turns in priority review voucher for supplemental indication on an old Celgene drug
Endpoints
Wed, 02/3/21 - 10:55 am
Bristol-Myers Squibb
Celgene
FDA
ulcerative colitis
priority review
Zeposia
Bristol Myers offloading Swiss tablet and capsule plant to Chinese CDMO WuXi STA
Fierce Pharma
Tue, 02/2/21 - 11:15 pm
Bristol-Myers Squibb
CDMO
China
WuXi Biologics
ISTA Pharmaceuticals
Merck's Keytruda Proves Better Alone in Combination Trial With BMS' Yervoy
BioSpace
Mon, 02/1/21 - 11:12 pm
Merck
Keytruda
Bristol-Myers Squibb
Yervoy
non-small cell lung cancer
WCLC: With Keytruda-Yervoy data, Merck casts doubt on Opdivo's place in lung cancer
Fierce Pharma
Sat, 01/30/21 - 11:32 pm
WCLC
Keytruda
Yervoy
Merck
Bristol-Myers Squibb
FDA blasts Lonza facility in Form 483 that derailed Bristol Myers' plan of liso-cel nod by 2020
Fierce Pharma
Fri, 01/29/21 - 09:57 am
Bristol-Myers Squibb
Celgene
liso-cel
M&A
CAR-T
Go or no go? Oncology decisions ahead for the FDA
EP Vantage
Wed, 01/27/21 - 11:55 am
FDA
cancer
oncology
Bristol-Myers Squibb
TG Therapeutics
Mallinckrodt
Sanofi
Regeneron
Sarepta Therapeutics
GSK
Oncopeptide
Bristol Myers, Exelixis snag Opdivo-Cabometyx kidney cancer nod to challenge Merck, Pfizer
Fierce Pharma
Mon, 01/25/21 - 11:09 am
Bristol-Myers Squibb
Exelixis
Opdivo
Cabometyx
kidney cancer
FDA
The top 10 largest biopharma M&A deals in 2020
Fierce Pharma
Tue, 01/19/21 - 10:30 am
M&A
AstraZeneca
Alexion
Bristol-Myers Squibb
MyoKardia
Gilead Sciences
Forty Seven
Merck
VelosBio
Nestle
Aimmune
Immunomedics
JNJ
Momenta Pharmaceuticals
Sanofi
Principia Biopharma
Bayer
Asklepios BioPharmaeutical
Aducanumab tops 2021’s biggest potential launches
EP Vantage
Mon, 01/18/21 - 01:04 pm
drug launches
Biogen
Eisai
aducanumab
efgartigimod
Argenx
Evrenzo
FibroGen
Astellas
AstraZeneca
Leqvio
Novartis
UCB Pharma
bimekizumab
Ascendis Pharma
Bluebird Bio
Bristol-Myers Squibb
ide-cel
liso-cel
AXS-05
Axsome Therapeutics
voclosporin
Aurinia
BMS Kicks Off 2021 with $70 Million Collab for Next-Gen T Cell Cancer Therapies
BioSpace
Thu, 01/7/21 - 12:35 pm
Bristol-Myers Squibb
ArsenalBio
solid tumors
t-cell therapies
Astrazeneca shows megamergers were still possible in 2020
EP Vantage
Wed, 01/6/21 - 10:41 am
M&A
AstraZeneca
Alexion
Bristol-Myers Squibb
MyoKardia
Bayer
Asklepios
Merck
VelosBio
Gilead Sciences
Forty Seven
Immunomedics
JNJ
Momenta
BMS/Celgene merger payout evaporates as CVR deadline passes
Pharmaforum
Mon, 01/4/21 - 10:21 am
Celgene
Bristol-Myers Squibb
FDA
CVRs
Corporate and regulatory developments over the holidays
EP Vantage
Mon, 01/4/21 - 10:20 am
AstraZeneca
Bristol-Myers Squibb
Celltrion
Cullinan Oncology
JNJ
Myovant Sciences
Osmotica Pharmaceuticals
Pfizer
Y-mAbs Therapeutics
United Therapeutics
Zai Lab
Merck, Bristol Myers, AstraZeneca and Roche lose bid to expand PD-1/L1 reach in China
Fierce Pharma
Wed, 12/30/20 - 10:53 am
Merck
Bristol-Myers Squibb
AstraZeneca
Roche
Keytruda
Opdivo
Imfinzi
Tecentriq
China
PD-1 inhibitors
Bristol Myers Squibb’s Opdivo Brain Tumor Trial Fails Mid-Trial Assessment
BioSpace
Sat, 12/26/20 - 08:07 pm
Bristol-Myers Squibb
Opdivo
clinical trials
brain tumors
Chasing BMS, J&J files BCMA CAR-T for multiple myeloma to FDA
Pharmaforum
Tue, 12/22/20 - 10:41 am
JNJ
Janssen
Multiple Myeloma
CAR-T
cilta-cel
FDA
Bristol-Myers Squibb
ide-cel
An FDA inspection raises questions about Bristol Myers Squibb's liso-cel facility and the CVR, but analysts urge caution
Endpoints
Tue, 12/8/20 - 10:41 am
Bristol-Myers Squibb
liso-cel
drug manufacturing
Celgene
CVRs
$200M investment to advance clinical programs for Ambrx
MedCity News
Mon, 11/23/20 - 10:18 pm
Ambrx
oncology
Astellas
BeiGene
Bristol-Myers Squibb

Pages